NCCN VERSION 2 2015

178 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-103
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
488. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus
vinorelbine or taxane chemotherapy for HER2-overexpressing
metastatic breast cancer: the trastuzumab and vinorelbine or taxane
study. Cancer 2007;110:965-972. Available at:
.
489. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III
study of trastuzumab, paclitaxel, and carboplatin compared with
trastuzumab and paclitaxel in women with HER-2-overexpressing
metastatic breast cancer. J Clin Oncol 2006;24:2786-2792. Available at:
.
490. Schaller G, Bangemann N, Weber J, et al. Efficacy and safety of
trastuzumab plus capecitabine in a German multicentre phase II study
of pre-treated metastatic breast cancer [abstract]. J Clin Oncol
2005;23(Suppl 16):Abstract 717. Available at:
.
491. Yamamoto D, Iwase S, Kitamura K, et al. A phase II study of
trastuzumab and capecitabine for patients with HER2-overexpressing
metastatic breast cancer: Japan Breast Cancer Research Network
(JBCRN) 00 Trial. Cancer Chemother Pharmacol 2008;61:509-514.
Available at: .
492. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the
trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221.
Available at: .
493. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and
trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol
2007;25:3853-3858. Available at:
.
494. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab
beyond progression in human epidermal growth factor receptor 2-
positive advanced breast cancer: a german breast group 26/breast
international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
Available at: .
495. Von Minckwitz G, Zielinski C, Maarteense E, et al. Capecitabine
vs. capecitabine + trastuzumab in patients with HER2-positive
metastatic breast cancer progressing during trastuzumab treatment:
The TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol
2008;26(Suppl 15):Abstract 1025. Available at:
.
496. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for
HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-
1791. Available at: .
497. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of
pertuzumab and trastuzumab in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer that progressed
during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144.
Available at: .
498. Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab
monotherapy after trastuzumab-based treatment and subsequent
reintroduction of trastuzumab: activity and tolerability in patients with
advanced human epidermal growth factor receptor 2-positive breast
cancer. J Clin Oncol 2012;30:1594-1600. Available at:
.
499. Geyer C, Forster J, Lindquist D, et al. Lapatinib plus capecitabine
for HER2-positive advanced breast cancer. N Engl J Med
2006;355:2733-2743. Available at:
.
500. Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in
women with HER-2-positive advanced breast cancer: final survival
analysis of a phase III randomized trial. Oncologist 2010;15:924-934.
Available at: .
501. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study
of lapatinib alone or in combination with trastuzumab in women with
ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin